skip to main content
Language:
Search Limited to: Search Limited to: Resource type Show Results with: Show Results with: Search type Index

Results 1 - 20 of 3,950  for All Library Resources

Sorted by: Sorted by: RelevanceOr hit Enter to replace sort method
Results 1 2 3 4 5 next page
Show only
Refined by: Journal Title: Cancers remove
Result Number Material Type Add to My Shelf Action Record Details and Options
1
The Current Status and Future Prospects of Oncolytic Viruses in Clinical Trials against Melanoma, Glioma, Pancreatic, and Breast Cancers
The Current Status and Future Prospects of Oncolytic Viruses in Clinical Trials against Melanoma, Glioma, Pancreatic, and Breast Cancers
Material Type:
Article 		Add to My Research

The Current Status and Future Prospects of Oncolytic Viruses in Clinical Trials against Melanoma, Glioma, Pancreatic, and Breast Cancers

Cancers, 2018-09, Vol.10 (10), p.356 [Peer Reviewed Journal]

2018 by the authors. 2018 ;ISSN: 2072-6694 ;EISSN: 2072-6694 ;DOI: 10.3390/cancers10100356 ;PMID: 30261620

Full text available

Citations Cited by
2
Oncologic Photodynamic Therapy: Basic Principles, Current Clinical Status and Future Directions
Oncologic Photodynamic Therapy: Basic Principles, Current Clinical Status and Future Directions
Material Type:
Article 		Add to My Research

Oncologic Photodynamic Therapy: Basic Principles, Current Clinical Status and Future Directions

Cancers, 2017-02, Vol.9 (2), p.19 [Peer Reviewed Journal]

Copyright MDPI AG 2017 ;2017 by the authors. 2017 ;ISSN: 2072-6694 ;EISSN: 2072-6694 ;DOI: 10.3390/cancers9020019 ;PMID: 28218708

Full text available

Citations Cited by
3
The Landscape of CAR-T Cell Clinical Trials against Solid Tumors—A Comprehensive Overview
The Landscape of CAR-T Cell Clinical Trials against Solid Tumors—A Comprehensive Overview
Material Type:
Article 		Add to My Research

The Landscape of CAR-T Cell Clinical Trials against Solid Tumors—A Comprehensive Overview

Cancers, 2020-09, Vol.12 (9), p.2567 [Peer Reviewed Journal]

COPYRIGHT 2020 MDPI AG ;2020. This work is licensed under http://creativecommons.org/licenses/by/3.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;2020 by the author. 2020 ;ISSN: 2072-6694 ;EISSN: 2072-6694 ;DOI: 10.3390/cancers12092567 ;PMID: 32916883

Full text available

Citations Cited by
4
Understanding MNPs Behaviour in Response to AMF in Biological Milieus and the Effects at the Cellular Level: Implications for a Rational Design That Drives Magnetic Hyperthermia Therapy toward Clinical Implementation
Understanding MNPs Behaviour in Response to AMF in Biological Milieus and the Effects at the Cellular Level: Implications for a Rational Design That Drives Magnetic Hyperthermia Therapy toward Clinical Implementation
Material Type:
Article 		Add to My Research

Understanding MNPs Behaviour in Response to AMF in Biological Milieus and the Effects at the Cellular Level: Implications for a Rational Design That Drives Magnetic Hyperthermia Therapy toward Clinical Implementation

Cancers, 2021-09, Vol.13 (18), p.4583 [Peer Reviewed Journal]

2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;2021 by the authors. 2021 ;ISSN: 2072-6694 ;EISSN: 2072-6694 ;DOI: 10.3390/cancers13184583 ;PMID: 34572810

Full text available

Citations Cited by
5
Photodynamic Therapy: A Compendium of Latest Reviews
Photodynamic Therapy: A Compendium of Latest Reviews
Material Type:
Article 		Add to My Research

Photodynamic Therapy: A Compendium of Latest Reviews

Cancers, 2021-09, Vol.13 (17), p.4447 [Peer Reviewed Journal]

2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;2021 by the authors. 2021 ;ISSN: 2072-6694 ;EISSN: 2072-6694 ;DOI: 10.3390/cancers13174447 ;PMID: 34503255

Full text available

Citations Cited by
6
Curcumin: Modulator of Key Molecular Signaling Pathways in Hormone-Independent Breast Cancer
Curcumin: Modulator of Key Molecular Signaling Pathways in Hormone-Independent Breast Cancer
Material Type:
Article 		Add to My Research

Curcumin: Modulator of Key Molecular Signaling Pathways in Hormone-Independent Breast Cancer

Cancers, 2021-07, Vol.13 (14), p.3427 [Peer Reviewed Journal]

2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;2021 by the authors. 2021 ;ISSN: 2072-6694 ;EISSN: 2072-6694 ;DOI: 10.3390/cancers13143427 ;PMID: 34298639

Full text available

Citations Cited by
7
Correction: Bailey et al. Clinical Trials in High-Risk Medulloblastoma: Evolution of the SIOP-Europe HR-MB Trial. Cancers 2022, 14 , 374
Correction: Bailey et al. Clinical Trials in High-Risk Medulloblastoma: Evolution of the SIOP-Europe HR-MB Trial. Cancers 2022, 14 , 374
Material Type:
Article 		Add to My Research

Correction: Bailey et al. Clinical Trials in High-Risk Medulloblastoma: Evolution of the SIOP-Europe HR-MB Trial. Cancers 2022, 14 , 374

Cancers, 2024-03, Vol.16 (6), p.1084 [Peer Reviewed Journal]

2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;2024 by the authors. 2024 ;ISSN: 2072-6694 ;EISSN: 2072-6694 ;DOI: 10.3390/cancers16061084 ;PMID: 38539574

Full text available

Citations Cited by
8
A Characterization of Dendritic Cells and Their Role in Immunotherapy in Glioblastoma: From Preclinical Studies to Clinical Trials
A Characterization of Dendritic Cells and Their Role in Immunotherapy in Glioblastoma: From Preclinical Studies to Clinical Trials
Material Type:
Article 		Add to My Research

A Characterization of Dendritic Cells and Their Role in Immunotherapy in Glioblastoma: From Preclinical Studies to Clinical Trials

Cancers, 2019-04, Vol.11 (4), p.537 [Peer Reviewed Journal]

2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;2019 by the authors. 2019 ;ISSN: 2072-6694 ;EISSN: 2072-6694 ;DOI: 10.3390/cancers11040537 ;PMID: 30991681

Full text available

Citations Cited by
9
Activation of Investigator-Initiated Clinical Trials with a Pharmaceutical for Cancer Patients before and after Post-Millennial Changes of Regulations in Germany and Europe
Activation of Investigator-Initiated Clinical Trials with a Pharmaceutical for Cancer Patients before and after Post-Millennial Changes of Regulations in Germany and Europe
Material Type:
Article 		Add to My Research

Activation of Investigator-Initiated Clinical Trials with a Pharmaceutical for Cancer Patients before and after Post-Millennial Changes of Regulations in Germany and Europe

Cancers, 2022-03, Vol.14 (5), p.1308 [Peer Reviewed Journal]

2022 by the author. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;2022 by the author. 2022 ;ISSN: 2072-6694 ;EISSN: 2072-6694 ;DOI: 10.3390/cancers14051308 ;PMID: 35267614

Full text available

Citations Cited by
10
Drugs Targeting p53 Mutations with FDA Approval and in Clinical Trials
Drugs Targeting p53 Mutations with FDA Approval and in Clinical Trials
Material Type:
Article 		Add to My Research

Drugs Targeting p53 Mutations with FDA Approval and in Clinical Trials

Cancers, 2023-01, Vol.15 (2), p.429 [Peer Reviewed Journal]

2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;2023 by the authors. 2023 ;ISSN: 2072-6694 ;EISSN: 2072-6694 ;DOI: 10.3390/cancers15020429 ;PMID: 36672377

Full text available

Citations Cited by
11
CD137 as an Attractive T Cell Co-Stimulatory Target in the TNFRSF for Immuno-Oncology Drug Development
CD137 as an Attractive T Cell Co-Stimulatory Target in the TNFRSF for Immuno-Oncology Drug Development
Material Type:
Article 		Add to My Research

CD137 as an Attractive T Cell Co-Stimulatory Target in the TNFRSF for Immuno-Oncology Drug Development

Cancers, 2021-05, Vol.13 (10), p.2288 [Peer Reviewed Journal]

2021 by the author. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;2021 by the author. 2021 ;ISSN: 2072-6694 ;EISSN: 2072-6694 ;DOI: 10.3390/cancers13102288 ;PMID: 34064598

Full text available

Citations Cited by
12
Tyrosine Kinase Inhibitors in Cancer: Breakthrough and Challenges of Targeted Therapy
Tyrosine Kinase Inhibitors in Cancer: Breakthrough and Challenges of Targeted Therapy
Material Type:
Article 		Add to My Research

Tyrosine Kinase Inhibitors in Cancer: Breakthrough and Challenges of Targeted Therapy

Cancers, 2020-03, Vol.12 (3), p.731 [Peer Reviewed Journal]

2020. This work is licensed under http://creativecommons.org/licenses/by/3.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;2020 by the authors. 2020 ;ISSN: 2072-6694 ;EISSN: 2072-6694 ;DOI: 10.3390/cancers12030731 ;PMID: 32244867

Full text available

Citations Cited by
13
MitoTam-01 Trial: Mitochondrial Targeting as Plausible Approach to Cancer Therapy. Comment on Yap et al. Complex I Inhibitor of Oxidative Phosphorylation in Advanced Solid Tumors and Acute Myeloid Leukemia: Phase I Trials. INat. Med./I 2023, I29/I, 115–126
MitoTam-01 Trial: Mitochondrial Targeting as Plausible Approach to Cancer Therapy. Comment on Yap et al. Complex I Inhibitor of Oxidative Phosphorylation in Advanced Solid Tumors and Acute Myeloid Leukemia: Phase I Trials. INat. Med./I 2023, I29/I, 115–126
Material Type:
Article 		Add to My Research

MitoTam-01 Trial: Mitochondrial Targeting as Plausible Approach to Cancer Therapy. Comment on Yap et al. Complex I Inhibitor of Oxidative Phosphorylation in Advanced Solid Tumors and Acute Myeloid Leukemia: Phase I Trials. INat. Med./I 2023, I29/I, 115–126

Cancers, 2023-09, Vol.15 (18) [Peer Reviewed Journal]

COPYRIGHT 2023 MDPI AG ;ISSN: 2072-6694 ;EISSN: 2072-6694 ;DOI: 10.3390/cancers15184476

Full text available

Citations Cited by
14
Association between Prior Malignancy Exclusion Criteria and Age Disparities in Cancer Clinical Trials
Association between Prior Malignancy Exclusion Criteria and Age Disparities in Cancer Clinical Trials
Material Type:
Article 		Add to My Research

Association between Prior Malignancy Exclusion Criteria and Age Disparities in Cancer Clinical Trials

Cancers, 2022-02, Vol.14 (4), p.1048 [Peer Reviewed Journal]

2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;2022 by the authors. 2022 ;ISSN: 2072-6694 ;EISSN: 2072-6694 ;DOI: 10.3390/cancers14041048 ;PMID: 35205795

Full text available

Citations Cited by
15
Treatment-Related Adverse Events of Chimeric Antigen Receptor T-Cell (CAR T) in Clinical Trials: A Systematic Review and Meta-Analysis
Treatment-Related Adverse Events of Chimeric Antigen Receptor T-Cell (CAR T) in Clinical Trials: A Systematic Review and Meta-Analysis
Material Type:
Article 		Add to My Research

Treatment-Related Adverse Events of Chimeric Antigen Receptor T-Cell (CAR T) in Clinical Trials: A Systematic Review and Meta-Analysis

Cancers, 2021-08, Vol.13 (15), p.3912 [Peer Reviewed Journal]

2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;2021 by the authors. 2021 ;ISSN: 2072-6694 ;EISSN: 2072-6694 ;DOI: 10.3390/cancers13153912 ;PMID: 34359816

Full text available

Citations Cited by
16
Blinded Independent Central Review (BICR) in New Therapeutic Lung Cancer Trials
Blinded Independent Central Review (BICR) in New Therapeutic Lung Cancer Trials
Material Type:
Article 		Add to My Research

Blinded Independent Central Review (BICR) in New Therapeutic Lung Cancer Trials

Cancers, 2021-09, Vol.13 (18), p.4533 [Peer Reviewed Journal]

2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;2021 by the authors. 2021 ;ISSN: 2072-6694 ;EISSN: 2072-6694 ;DOI: 10.3390/cancers13184533 ;PMID: 34572761

Full text available

Citations Cited by
17
Light Technology for Efficient and Effective Photodynamic Therapy: A Critical Review
Light Technology for Efficient and Effective Photodynamic Therapy: A Critical Review
Material Type:
Article 		Add to My Research

Light Technology for Efficient and Effective Photodynamic Therapy: A Critical Review

Cancers, 2021-07, Vol.13 (14), p.3484 [Peer Reviewed Journal]

2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;2021 by the authors. 2021 ;ISSN: 2072-6694 ;EISSN: 2072-6694 ;DOI: 10.3390/cancers13143484 ;PMID: 34298707

Full text available

Citations Cited by
18
Tumor-Treating Fields in Glioblastomas: Past, Present, and Future
Tumor-Treating Fields in Glioblastomas: Past, Present, and Future
Material Type:
Article 		Add to My Research

Tumor-Treating Fields in Glioblastomas: Past, Present, and Future

Cancers, 2022-07, Vol.14 (15), p.3669 [Peer Reviewed Journal]

2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;2022 by the authors. 2022 ;ISSN: 2072-6694 ;EISSN: 2072-6694 ;DOI: 10.3390/cancers14153669 ;PMID: 35954334

Full text available

Citations Cited by
19
Lenvatinib as an Initial Treatment in Patients with Intermediate-Stage Hepatocellular Carcinoma Beyond Up-To-Seven Criteria and Child-Pugh A Liver Function: A Proof-Of-Concept Study
Lenvatinib as an Initial Treatment in Patients with Intermediate-Stage Hepatocellular Carcinoma Beyond Up-To-Seven Criteria and Child-Pugh A Liver Function: A Proof-Of-Concept Study
Material Type:
Article 		Add to My Research

Lenvatinib as an Initial Treatment in Patients with Intermediate-Stage Hepatocellular Carcinoma Beyond Up-To-Seven Criteria and Child-Pugh A Liver Function: A Proof-Of-Concept Study

Cancers, 2019-07, Vol.11 (8), p.1084 [Peer Reviewed Journal]

2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;2019 by the authors. 2019 ;ISSN: 2072-6694 ;EISSN: 2072-6694 ;DOI: 10.3390/cancers11081084 ;PMID: 31370183

Full text available

Citations Cited by
20
Systematic Review on CAR-T Cell Clinical Trials Up to 2022: Academic Center Input
Systematic Review on CAR-T Cell Clinical Trials Up to 2022: Academic Center Input
Material Type:
Article 		Add to My Research

Systematic Review on CAR-T Cell Clinical Trials Up to 2022: Academic Center Input

Cancers, 2023-02, Vol.15 (4), p.1003 [Peer Reviewed Journal]

COPYRIGHT 2023 MDPI AG ;2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;Distributed under a Creative Commons Attribution 4.0 International License ;2023 by the authors. 2023 ;ISSN: 2072-6694 ;EISSN: 2072-6694 ;DOI: 10.3390/cancers15041003 ;PMID: 36831349

Full text available

Citations Cited by

Results 1 - 20 of 3,950  for All Library Resources

Sorted by: Sorted by: RelevanceOr hit Enter to replace sort method
Results 1 2 3 4 5 next page

Personalize your results

  1. Edit

Refine Search Results

Expand My Results

  1.   

Show only

  1. Peer-reviewed Journals (3,949)
INSPIRE LIBRARY - TON DUC THANG UNIVERSITY (84-028) 37 755 057 Feedback
19 Nguyen Huu Tho St. Dist.7, HCM thuvien@tdtu.edu.vn

Copyright © 2017 INSPIRE LIBRARY - TON DUC THANG UNIVERSITY

Searching Remote Databases, Please Wait